中文  |  EN

搜索

News Center

Hubei Meilin Pharmaceutical Co., Ltd. was completed and put into production

Hubei Meilin Pharmaceutical Co., Ltd. was established in April 2010. It is a diversified compound pharmaceutical production company with self-research, production and sales, and joint research, production and sales. It is mainly engaged in the research and development and production of chemical raw materials and preparations. ,Sales.
27 2021/09

News analysis: Where did you go to find the new crown drug?

Medical Network, August 24th: Although the new crown vaccine has been vaccinated in many countries on a large scale, the global epidemic is still continuing. The challenge of the mutated virus to the vaccine has also made scientists aware of the urgency of developing therapeutic drugs. Recently, the World Health Organization launched the "Unity Test+" project to find new crown treatment drugs in a new stage, and some research teams have also announced new developments in research and development.
24 2021/08

End of the pilot, innovation and start again

Medical Network News on August 23  As soon as the pilot work of traditional Chinese medicine formula granules ended, a new wave of innovation surged across the face. According to data from the Public Opinion Monitoring Center of China Health Media Group: On February 10 this year, the State Food and Drug Administration and the State Administration of Traditional Chinese Medicine jointly issued the "Announcement on Ending the Pilot Work of Chinese Medicine Formula Granules" (hereinafter referred to as the "Announcement") , Decided to end the pilot work of traditional Chinese medicine formula granules, and clarified the supervision matters after the pilot work. After the announcement of the "Announcement", various provincial drug regulatory authorities have successively issued the working procedures for formulating the quality standards of traditional Chinese medicine formula granules and the requirements for application materials, and the implementation rules have been issued in many places to actively implement the requirements of the "Announcement", and the policy of traditional Chinese medicine formula granules has accelerated.
23 2021/08

The list of key monitoring drugs may be adjusted every two years, and 30 varieties will be included

Medical Network News on August 23. Following the start of a new round of adjustments to the medical insurance catalogue and repeated news about the adjustment of the basic medicine catalogue, the key monitoring drug catalogue is also about to be adjusted. The catalogue previously included 20 varieties, which may reach 30 after the adjustment. Varieties.
23 2021/08

Offline supervision of pharmacies and cross-departmental “joint inspections” in many places

Pharmaceutical Net News on August 20: The supervision of pharmacies has changed, and cross-departmental joint inspections have become a national trend. Medical insurance designated pharmacies, inter-departmental joint supervision On August 17, the People's Government of Fenghua District, Ningbo City issued the "Notice on the Inter-departmental Joint Inspection of Designated Retail Pharmacies" (hereinafter referred to as the "Notice").
20 2021/08

R&D internal volume and admission rate is only 25%! How to reconstruct the pattern of innovative drugs under the New Deal?

Medical News, August 20: On July 2, the Center for Drug Evaluation (CDE) of the State Food and Drug Administration issued the "Clinical Value-Oriented Anti-tumor Drug Clinical Development Guidelines" for soliciting comments (hereinafter referred to as the "Guiding Principles"). One stone caused a thousand waves of waves, and the capital market responded strongly, and the pharmaceutical stock index fell for many days. "Moutai in Medicine" Hengrui Medicine has fallen from the throne of the pharmaceutical stock market value, ranking behind the leading medical device Mindray Medical and the leading pharmaceutical outsourcing service WuXi AppTec. This policy is tantamount to bringing an "ice bucket challenge" to the burgeoning Chinese innovative medicine industry.
20 2021/08
Previous page
1
2
Links

Links

CFDA
E-mail

Business Email:hbmlyy@merriclin.cn    HR Email:hr@merriclin.cn

address

Company address:No. 8 Heping Road, Economic Development Zone, Yunmeng County, Xiaogan, Hubei    Postal code:432500    This website supports IPV6

copyright

Copyright © 2012-2021  Hubei Merriclin Pharmaceutical Co.,Ltd.     Powered by www.300.cn

filing

Filing information:鄂公网安备42092300000000号    鄂ICP备20010943号-1  《Internet  information service qualification certificate》No.(E) - non operating-2020-0023

operation

Operation information: the website has been running for 00001 days. It is recommended to use the browser based on chromium core to browse the website at a resolution of no less than 1920 * 1280px to obtain good browsing effect.

Merriclin Official Website

Merriclin Official Website

 Merriclin WeChat Official

 Merriclin WeChat Official